drugset

drugset / Trial / NCT06688799

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

NCT06688799 ↗

Phase 1/2 Recruiting 18 enrolled Beijing GoBroad Hospital

NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to evaluate the safety and effi cacy of CD19 CAR T cells in the treatment of Refractory Autoimmune Diseases.

Timeline

Start: 2024-11-23
Primary completion: 2026-03
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD19 CAR-T cells	Cell therapy	—	—

Indications